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Pioglitazone, Vitamin E, or Placebo
for Nonalcoholic Steatohepatitis
Arun J. Sanyal, M.D., Naga Chalasani, M.B., B.S., Kris V. Kowdley, M.D.,
Arthur McCullough, M.D., Anna Mae Diehl, M.D., Nathan M. Bass, M.D., Ph.D.,
Brent A. Neuschwander-Tetri, M.D., Joel E. Lavine, M.D., Ph.D.,
James Tonascia, Ph.D., Aynur Unalp, M.D., Ph.D., Mark Van Natta, M.H.S.,
Jeanne Clark, M.D., M.P.H., Elizabeth M. Brunt, M.D.,
David E. Kleiner, M.D., Ph.D., Jay H. Hoofnagle, M.D.,
and Patricia R. Robuck, Ph.D., M.P.H., for the NASH CRN*

A BS T R AC T
Background

Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrho
sis. Currently, there is no established treatment for this disease.
Methods

We randomly assigned 247 adults with nonalcoholic steatohepatitis and without dia
betes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a
dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96 weeks. The pri
mary outcome was an improvement in histologic features of nonalcoholic steato
hepatitis, as assessed with the use of a composite of standardized scores for steato
sis, lobular inflammation, hepatocellular ballooning, and fibrosis. Given the two
planned primary comparisons, P values of less than 0.025 were considered to indi
cate statistical significance.
Results

Vitamin E therapy, as compared with placebo, was associated with a significantly
higher rate of improvement in nonalcoholic steatohepatitis (43% vs. 19%, P = 0.001),
but the difference in the rate of improvement with pioglitazone as compared with
placebo was not significant (34% and 19%, respectively; P = 0.04). Serum alanine
and aspartate aminotransferase levels were reduced with vitamin E and with pio
glitazone, as compared with placebo (P<0.001 for both comparisons), and both
agents were associated with reductions in hepatic steatosis (P = 0.005 for vitamin E
and P<0.001 for pioglitazone) and lobular inflammation (P = 0.02 for vitamin E and
P = 0.004 for pioglitazone) but not with improvement in fibrosis scores (P = 0.24 for
vitamin E and P = 0.12 for pioglitazone). Subjects who received pioglitazone gained
more weight than did those who received vitamin E or placebo; the rates of other side
effects were similar among the three groups.
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Copyright © 2010 Massachusetts Medical Society.

Conclusions

Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis
in adults without diabetes. There was no benefit of pioglitazone over placebo for
the primary outcome; however, significant benefits of pioglitazone were observed
for some of the secondary outcomes. (ClinicalTrials.gov number, NCT00063622.)
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onalcoholic steatohepatitis is a
common liver disease that is character
ized histologically by hepatic steatosis,
lobular inflammation, and hepatocellular balloon
ing1,2; it can progress to cirrhosis in up to 15% of
patients.3,4 There is currently no therapy that is
of proven benefit for nonalcoholic steatohepati
tis. The disease is closely associated with insulin
resistance and features of the metabolic syndrome
such as obesity, hypertriglyceridemia, and type 2
diabetes.5,6 In addition to insulin resistance, oxi
dative stress has been implicated as a key factor
contributing to hepatic injury in patients with
nonalcoholic steatohepatitis.6,7 Thus, both insulin
resistance and oxidative stress are attractive tar
gets for therapy in patients with this disease.
Several pilot studies have provided evidence that
insulin sensitizers such as thiazolidinediones and
antioxidants such as vitamin E improve clinical
and histologic features of nonalcoholic steato
hepatitis.8-14 The medical evidence of a benefit,
however, is limited, because these studies had
small samples and were performed at single cen
ters. Moreover, a recent multicenter trial showed
a reduction in hepatic steatosis but no improve
ment in markers of cell injury after a year of
rosiglitazone therapy.15 The value of these drugs
remains uncertain.
The Nonalcoholic Steatohepatitis Clinical Re
search Network (NASH CRN) was established by
the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) to address unmet
research needs in the field. As a part of this man
date, the NASH CRN conducted the Pioglitazone
versus Vitamin E versus Placebo for the Treatment
of Nondiabetic Patients with Nonalcoholic Steato
hepatitis (PIVENS) trial, a phase 3, multicenter,
randomized, placebo-controlled, double-blind
clinical trial of pioglitazone or vitamin E for the
treatment of adults without diabetes who had
biopsy-confirmed nonalcoholic steatohepatitis.

Me thods
Study Oversight

The PIVENS protocol and consent forms were de
signed by a subcommittee and approved by the
steering committee of the CRN (see the Appen
dix). The study was approved by the review board
at each participating center, and all subjects gave
written informed consent. The study was con
ducted by site investigators, and data were gath
1676
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ered by specifically trained personnel. The data
were analyzed at the data coordinating center and
were reviewed by both the investigators and an
independent data and safety monitoring board.
The manuscript was written by a CRN subcom
mittee and approved by the members of the steer
ing committee, who assume responsibility for the
integrity of the data and the overall content of the
manuscript.
Study Design

The trial design and rationale for the PIVENS trial
have been described previously.16 This trial fo
cused on adults without diabetes who had nonal
coholic steatohepatitis. Adults with diabetes were
excluded because it was unclear whether they
would have the same responses to therapy as
would adults without diabetes and because it was
possible that changes in antidiabetic therapy might
confound the analysis of data both from subjects
with diabetes and from those without diabetes. All
subjects underwent a liver biopsy within 6 months
before randomization.
Steatohepatitis was categorized as absent, pos
sible, or definite.17 Disease activity was assessed
with the use of the nonalcoholic fatty liver disease
activity score, which is based on a standardized
grading system for steatosis (on a scale of 0 to 3),
lobular inflammation (on a scale of 0 to 3), and
hepatocellular ballooning (on a scale of 0 to 2),
with higher scores indicating increasing severity).17
The specific inclusion criteria were definite or
possible steatohepatitis with an activity score of
5 or more, or definite steatohepatitis (confirmed
by two pathologists) with an activity score of 4.
A score of at least 1 for hepatocellular ballooning
was required in all cases. Although eligibility was
determined by the pathologist at each site from an
assessment of tissue sections prepared locally, the
final analysis was based on review by a pathology
committee of deeper cuts, prepared centrally, from
the biopsy specimens obtained at baseline and at
the end of treatment. Members of the pathology
committee who performed the final analysis were
unaware of the study-group assignments.
Exclusion criteria were alcohol consumption of
more than 20 g per day in the case of women and
more than 30 g per day in the case of men for at
least 3 consecutive months during the previous
5 years, as assessed with the use of the Lifetime
Drinking History questionnaire of Skinner et al.18
and the self-administered Alcohol Use and Disor
nejm.org
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ders Identification Test (AUDIT).19 Subjects were
also excluded if they had cirrhosis, hepatitis C or
other liver diseases, or heart failure (New York
Heart Association class II to IV), or if they were
receiving drugs known to cause steatohepatitis.
Both at the initial evaluation and at the com
pletion of treatment 96 weeks later, subjects un
derwent an assessment of body weight, height,
and waist and hip circumferences, and blood
samples were obtained for routine biochemical
tests and assessment of fasting levels of lipids,
glucose, and insulin. Body composition was as
sessed with the use of dual-energy x-ray absorp
tiometry. The Medical Outcomes Study 36-Item
Short-Form Health Survey (SF-36) was adminis
tered for the assessment of quality of life.
Randomization and Treatment Groups

Subjects who met all eligibility criteria and pro
vided written informed consent were randomly
assigned to one of three groups for 96 weeks of
study treatment: a group receiving pioglitazone
(at a dose of 30 mg once daily) and a vitamin
E–like placebo (once daily), a group receiving vi
tamin E (800 IU, natural form, once daily) and a
pioglitazone-like placebo (once daily); or a group
receiving a pioglitazone-like placebo (once daily)
and a vitamin E–like placebo (once daily). The
30-mg pioglitazone tablets (Actos) and similarappearing placebo tablets were provided by Take
da Pharmaceuticals North America under a col
laborative research and development agreement
with the NIDDK. The 800-IU liquid soft-gelatin
capsules of RRR-α-tocopherol (formerly known
as d-α-tocopherol) vitamin E (Nature Made) and
similar-appearing placebo soft-gelatin capsules
were provided by Pharmavite under a clinical
trial agreement with the NIDDK. Both Takeda
and Pharmavite provided comments regarding
the study design but were not involved in the
writing of the protocol, the conduct of the trial,
the decision-making with respect to the trial, or
the analysis of the data. Both companies were
shown a draft of the manuscript 30 days before it
was submitted for publication but were not in
volved in the preparation of the manuscript. The
doses were selected on the basis of previous phase
2 studies.9,13

ment of the safety and tolerability of the study
drugs. Subjects were discouraged from adding
other drugs that are used for nonalcoholic steato
hepatitis to their regimen. All subjects were given
a standardized set of pragmatic recommendations
about lifestyle changes and diet. A liver biopsy was
performed 96 weeks after randomization, after
which the study drugs were discontinued. Subjects
were then followed for an additional 24 weeks.
Primary and Secondary Outcomes

The primary outcome was an improvement in his
tologic findings, which required an improvement
by 1 or more points in the hepatocellular balloon
ing score; no increase in the fibrosis score; and
either a decrease in the activity score for nonalco
holic fatty liver disease to a score of 3 or less or a
decrease in the activity score of at least 2 points,
with at least a 1-point decrease in either the lobu
lar inflammation or steatosis score.
Secondary outcomes included changes in the
overall activity score for nonalcoholic fatty liver
disease, as well as in individual component scores
for steatosis, lobular inflammation, hepatocel
lular ballooning, and fibrosis, and changes in se
rum aminotransferase levels, anthropometric mea
sures, and insulin resistance and lipid profiles.
An additional secondary outcome was the change
in health-related quality of life from baseline to
the end of treatment, as assessed with the use of
the SF-36.
Statistical Analysis

The primary analysis was an intention-to-treat
analysis in which the proportions of subjects in
each active-treatment group (pioglitazone and vi
tamin E) in whom there was improvement in non
alcoholic steatohepatitis were compared with the
proportion of subjects in the placebo group in
whom there was improvement. Comparisons were
made with the use of the Mantel–Haenszel chisquare test, stratified according to clinical site.
Subjects who did not undergo an end-of-treatment
biopsy were classified as not having had improve
ment. Given the fact that there were two planned
primary comparisons, Bonferroni-adjusted P val
ues of less than 0.025 were considered to indicate
statistical significance. The number of subjects
who would need to be treated to achieve histo
Follow-up Visits
logic improvement in one patient was calculated
After randomization, subjects were followed ac for the vitamin E and pioglitazone treatments.
cording to a predetermined schedule for assess We analyzed secondary outcomes with the use of
n engl j med 362;18
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Fisher’s exact test for binary outcomes and analy
sis-of-covariance models for continuous outcomes,
regressing change from baseline to 96 weeks on
treatment group and baseline value of the out
come variable in order to adjust comparisons of
mean changes in secondary outcomes for the base
line value of the outcome variable.
The planned sample size was 240 subjects, with
equal assignment to each of the three study groups
(80 per group). We estimated that with this sample
size, the study would have 90% power to detect
an absolute difference in the rate of improvement
in nonalcoholic steatohepatitis of 26 percentage
points, with a two-sided type 1 error of 0.025.16
An independent data and safety monitoring board
appointed by the NIDDK monitored the results
semiannually; O’Brien–Fleming statistical stop
ping guidelines were used, with one interim
analysis for efficacy performed midway through
the trial.

R e sult s
Study Subjects

Subjects were enrolled in the trial between Janu
ary 2005 and January 2007 and were treated and
followed for 96 weeks (Fig. 1). Of the 247 sub
jects who underwent randomization, 83 were as
signed to receive placebo, 84 were assigned to re
ceive vitamin E, and 80 were assigned to receive
pioglitazone. The three groups were well matched
with respect to demographic characteristics, clini
cal and laboratory data, and activity scores for
nonalcoholic fatty liver disease (Table 1). However,
according to the planned, blinded, central analy
sis of liver-biopsy specimens, 17% of the subjects
in the placebo group, 18% of those in the vita
min E group, and 28% of those in the pioglitazone
group did not have hepatocellular ballooning on
assessment of their initial biopsy specimen.
Primary Outcome

A total of 90% of the subjects underwent an endof-treatment liver biopsy at 96 weeks. Vitamin E
therapy, as compared with placebo, was associated
with a significantly higher rate of improvement
in nonalcoholic steatohepatitis (43% vs. 19%,
P = 0.001; number needed to treat, 4.2), but the
comparison of pioglitazone therapy with placebo
did not reach the prespecified 0.025 level of sig
nificance for the primary outcome (34% vs. 19%,
P = 0.04; number needed to treat, 6.9) (Table 2).
1678
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Given the subjectivity of histologic analysis,
several sensitivity analyses were performed. If a
finding of no worsening (rather than improve
ment) of hepatocellular ballooning was used as
a criterion in the outcome measure, both active
drugs were significantly associated with an im
provement in histologic features of nonalcoholic
steatohepatitis, as compared with placebo (pla
cebo vs. vitamin E: 25% vs. 51% improvement,
P<0.001; placebo vs. pioglitazone: 25% vs. 48%,
P = 0.003). When subjects who did not have hepa
tocellular ballooning initially, as assessed by cen
tral review, were excluded from the analyses, both
active drug groups were associated with a signifi
cant improvement in histologic findings (placebo
vs. vitamin E: 23% vs. 52% improvement, P<0.001;
placebo vs. pioglitazone: 23% vs. 47%, P = 0.002).
An analysis of baseline factors to identify char
acteristics associated with a histologic response
to either active treatment did not reveal any sig
nificant findings, and the data were consistent
across all subgroups that were analyzed (Table 10
in the Supplementary Appendix, available with the
full text of this article at NEJM.org).
Secondary Outcomes

Histologic Features

As compared with the placebo group, both ac
tive-treatment groups had a significant reduction
in steatosis, lobular inflammation (Fig. 1 in the
Supplementary Appendix), and the activity score
for nonalcoholic fatty liver disease (Table 2). Al
though scores for hepatocellular ballooning were
improved with vitamin E and with pioglitazone,
only the improvement with vitamin E was signifi
cant (P = 0.01). Fibrosis scores were not signifi
cantly improved with either active treatment. Ste
atohepatitis resolved in a greater proportion of
subjects receiving either vitamin E or pioglitazone
than in those receiving placebo, but the difference
was significant only for those receiving pioglita
zone (P = 0.001) (Table 2).
Serum Enzyme Levels and Liver Test Results

There was an early and highly significant decrease
in mean aspartate aminotransferase and alanine
aminotransferase levels among subjects receiving
vitamin E and among subjects receiving pioglita
zone (Fig. 2). These changes occurred in the first
24 weeks and were sustained throughout the pe
riod in which the subjects were receiving treat
ment. Serum concentrations of alkaline phospha
nejm.org
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339 Patients were assessed for eligibility

92 Were excluded
82 Did not meet inclusion criteria
7 Declined to participate
3 Had other reasons

247 Underwent randomization

83 Were assigned to receive
placebo

84 Were assigned to receive
vitamin E

80 Were assigned to receive
pioglitazone

83 Received placebo

84 Received vitamin E

80 Received pioglitazone

6 Stopped treatment before
96 wk
3 Were withdrawn by
physician
2 Were lost to follow-up
1 Declined to participate

12 Stopped treatment before
96 wk
1 Was withdrawn by
physician
11 Were lost to follow-up

83 Were included in analysis
of primary outcome
72 Underwent baseline and
end-of-study biopsies
11 Had missing biopsy at 96 wk
imputed as no improvement
2 Declined to participate
5 Were lost to follow-up
4 Withdrew from study

84 Were included in analysis
of primary outcome
80 Underwent baseline and
end-of-study biopsies
4 Had missing biopsy at 96 wk
imputed as no improvement
2 Declined to participate
1 Was lost to follow-up
1 Had a contraindication

14 Stopped treatment before
96 wk
1 Was withdrawn by
physician
11 Were lost to follow-up
2 Declined to participate

80 Were included in analysis
of primary outcome
70 Underwent baseline and
end-of-study biopsies
10 Had missing biopsy at 96 wk
imputed as no improvement
6 Were lost to follow-up
4 Withdrew from study

Figure 1. Screening, Randomization, and Follow-up of Study Subjects.

tase and γ-glutamyl transpeptidase also improved versed. Changes in quality of life, as assessed by
in the two active-drug groups, but bilirubin lev the scores for both the mental and physical com
els did not change significantly.
ponents of the SF-36, did not differ significantly
between the vitamin E group or the pioglitazone
Body Weight, Insulin Resistance, and Quality of Life group and the placebo group (Table 3).
There was a significant improvement in insulin
resistance only in the pioglitazone group, but that Adverse Events
group was also the only group that had a signifi With the exception of weight gain, the overall dis
cant mean weight gain (a mean increase of 4.7 kg tribution of individual adverse events did not dif
at week 96, P<0.001 for the comparison with pla fer significantly across the study groups. There
cebo) (Table 3). These changes were noted by week were 19 severe adverse events — 10 in the place
24, and the weight gain progressed over the course bo group, 7 in the vitamin E group, and 2 in the
of the study. Although insulin resistance returned pioglitazone group (see Table 3 in the Supplemen
to the baseline value after discontinuation of pio tary Appendix for details). A similar number of
glitazone, the associated weight gain was not re cardiovascular events occurred among subjects
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Table 1. Baseline Characteristics of the Study Subjects.*
Characteristic

Placebo (N = 83)

Vitamin E (N = 84)

Pioglitazone (N = 80)

Total (N = 247)

45.4±11.2

46.6±12.1

47.0±12.6

46.3±11.9

58

62

59

60

Hispanic

7

19

19

15

Nonwhite

11

15

8

12

SF-36, physical component

47±11

49±10

49±9

48±10

SF-36, mental component

47±12

49±10

49±8

48±10

Alanine aminotransferase (U/liter)

81±48

86±52

82±45

83±49

Aspartate aminotransferase (U/liter)

55±30

59±33

54±26

56±30

γ-Glutamyltransferase (U/liter)

69±79

56±42

60±63

61±63

Alkaline phosphatase (U/liter)

82±25

77±25

86±39

81±30

0.76±0.35

0.75±0.38

0.77±0.38

0.76±0.37

165±89

166±104

162±84

165±93

Demographic factors
Age (yr)
Female sex (%)
Race or ethnic group (%)†

Quality of life‡

Serum biochemical levels

Total bilirubin (mg/dl)
Lipids
Triglycerides (mg/dl)
Cholesterol (mg/dl)
Total

199±40

195±40

195±37

196±39

High-density lipoprotein

43±11

44±13

45±12

44±12

Low-density lipoprotein

125±35

119±35

120±31

122±34

Fasting serum glucose (mg/dl)

95±14

95±14

92±12

94±13

Insulin resistance§

5.5±5.1

5.2±4.0

5.0±3.8

5.2±4.3

Weight (kg)

99±21

94±24

97±23

97±23

Body-mass index¶

35±7

34±7

34±6

34±7

Waist circumference (cm)

109±14

107±15

108±14

108±14

Body composition (% fat)

40±9

39±9

40±8

39±9
4.9±1.4

Metabolic factors

Liver histologic findings‖
Total NAFLD activity score

4.8±1.4

5.1±1.4

5.0±1.4

Steatosis

1.9±0.8

1.9±0.9

2.0±0.8

1.9±0.8

Lobular inflammation

1.6±.0.7

1.8±0.7

1.8±0.7

1.7±0.7

Hepatocellular ballooning
Fibrosis stage**
Absence of ballooning on central review (%)

1.3±0.7

1.3±0.8

1.1±0.8

1.3±0.8

1.6±1.1

1.5±1.0

1.4±0.9

1.5±1.0

17

18

28

21

*		 Plus–minus values are means ±SD. To convert the values for bilirubin to micromoles per liter, multiply by 17.1. To convert the values for
triglycerides to millimoles per liter, multiply by 0.01129. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586.
To convert the values for glucose to millimoles per liter, multiply by 0.05551.
†		 Race or ethnic group was self-reported.
‡		 Scores on the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) were standardized to the 1998 U.S. general population
with a mean (±SD) of 50±10.
§		 The homeostasis model assessment for insulin resistance (HOMA-IR) was used to calculate insulin resistance, according to the following
formula: (milligrams of glucose per deciliter × microunits of insulin per milliliter) ÷ 405. Higher numbers indicate greater insulin resistance.
¶		 The body-mass index is the weight in kilograms divided by the square of the height in meters.
‖		 Total nonalcoholic fatty liver disease (NAFLD) activity was assessed on a scale of 0 to 8, with higher scores indicating more severe disease;
the components of this measure include steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3),
and hepatocellular ballooning (assessed on a scale of 0 to 2).
** Fibrosis was assessed on a scale of 0 to 4, with higher scores indicating more severe fibrosis.

1680
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Table 2. Primary Outcome and Changes in Histologic Features of the Liver after 96 Weeks of Treatment.
Variable

Placebo

Vitamin E

Pioglitazone

P Value*
Vitamin E Pioglitazone
vs. Placebo vs. Placebo

Primary outcome†
No. of subjects randomly assigned

83

84

80

Subjects with improvement (%)

19

43

34

72

80

70

Subjects with improvement (%)

31

54

69

Mean change in score

−0.1

−0.7

−0.8

Subjects with improvement (%)

35

54

60

0.02

0.004

Mean change in score

−0.2

−0.6

−0.7

0.008

<0.001

29

50

44

0.01

0.08

0.001

0.04

Changes from baseline in histologic features
No. of subjects with biopsy specimens at baseline
and 96 wk
Steatosis
0.005

<0.001

<0.001

<0.001

Lobular inflammation

Hepatocellular ballooning
Subjects with improvement (%)
Mean change in score
Total NAFLD activity score (mean change)

−0.2

−0.5

−0.4

0.03

0.01

−0.5

−1.9

−1.9

<0.001

<0.001

31

41

44

0.24

0.12

Fibrosis‡
Subjects with improvement (%)
Mean change in score
Resolution of definite nonalcoholic steatohepatitis
(% of subjects)

−0.1

−0.3

−0.4

0.19

0.10

21

36

47

0.05

0.001

* P values were calculated with the use of the Mantel–Haenszel chi-square test, stratified according to clinic, for the primary outcome; Fisher’s exact test for the binary secondary outcomes; and analysis-of-covariance models, regressing
change from baseline to 96 weeks on treatment group and baseline value of the outcome, for secondary outcome
scores.
† The primary outcome was an improvement in histologic findings, which required improvement by 1 or more points in
the hepatocellular ballooning score; no increase in the fibrosis score; and either a decrease in the activity score for nonalcoholic fatty liver disease to a score of 3 points or less or a decrease in the activity score of at least 2 points, with at
least a 1-point decrease in either the lobular inflammation or steatosis score. A total of 11 subjects in the placebo
group, 4 in the vitamin E group, and 10 in the pioglitazone group had missing histologic data at week 96, and the results for these subjects were imputed as a lack of improvement. The NAFLD activity score was assessed on a scale of 0
to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (assessed
on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on
a scale of 0 to 2).
‡ Fibrosis was assessed on a scale of 0 to 4, with higher scores indicating more severe fibrosis.

taking placebo (12 events), those taking vitamin E
(12), and those taking pioglitazone (10). No cases
of congestive heart failure were reported. The fre
quency of bone fractures was also similar across
study groups: five in the placebo group, three in
the vitamin E group, and three in the pioglita
zone group. During the 96 weeks of the study,
diabetes developed in four subjects who were re
ceiving vitamin E but in none of the subjects who
were receiving placebo or pioglitazone (P = 0.12
for the comparison of vitamin E with placebo).
Symptoms and signs of cirrhosis (thrombocytope
n engl j med 362;18

nia, anasarca, and hyperbilirubinemia) developed
in one patient in the vitamin E group who had
had bridging hepatic fibrosis at entry, and that
patient died of sepsis. No cases of serious hepa
totoxicity requiring permanent discontinuation of
the study drug were reported.

Discussion
The assessment of therapeutic agents for nonal
coholic steatohepatitis is a complex process. Be
cause there are no validated biomarkers of response
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Figure 2. Changes from Baseline in Aminotransferase Levels, Insulin Resistance, and Weight, According to Study Group.
Mean values are shown for changes from baseline (the value at follow-up minus the baseline value) in alanine aminotransferase levels,
aspartate aminotransferase levels, insulin resistance, and weight among the 83 subjects in the placebo group, 84 subjects in the vitamin
E group, and 80 subjects in the pioglitazone group. All available data were included in the calculation of means; data were missing for
less than 10% of subjects. Insulin resistance was calculated according to the homeostasis model assessment, with the use of the following formula: (milligrams of glucose per deciliter × microunits of insulin per milliliter) ÷ 405.

to treatment, one must rely on histologic assess
ment of a liver-biopsy specimen for this purpose.
The activity score for nonalcoholic fatty liver dis
ease quantifies the severity of steatosis, hepato
cellular ballooning, and inflammation — the key
histologic components of the disease.17 A decrease
in their severity occurs with amelioration of the
disease; however, the severity of these components
(especially hepatic steatosis) may also decrease with
progression of fibrosis to cirrhosis.20,21
To develop an outcome that was both quanti
fiable and clinically relevant, the requirements of
an improvement in ballooning and no worsening
of fibrosis were added to the requirement of a
decrease in the nonalcoholic fatty liver disease
activity score for the primary outcome. This makes
it likely that the observed improvements with vi
tamin E are both statistically and clinically sig
nificant. These improvements are also concordant
with those in previous small, pilot trials.12,13 These
data cannot, however, be generalized to patients
1682
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with diabetes or to those with cirrhosis, and ad
ditional clinical trials both to confirm these find
ings and to determine the generalizability of the
data are warranted.
Although pioglitazone did not meet the pre
specified significance level for the primary out
come, it was associated with highly significant
reductions in steatosis, inflammation, and hepato
cellular ballooning, as well as with improvements
in insulin resistance and liver-enzyme levels (Table
2 and Fig. 2). It also led to the resolution of
steatohepatitis in a significant proportion of
subjects. One possible reason for the failure to
achieve the primary outcome with pioglitazone
therapy, even though it significantly improved in
dividual features of nonalcoholic steatohepatitis,
is that more subjects in the pioglitazone group
than in the vitamin E and placebo groups were
classified as not having had ballooning, on the
basis of the planned central review of deeper cuts
of baseline biopsy specimens, and a reduction in
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Table 3. Changes in Serum Biochemical Levels, Metabolic Factors, and Quality of Life from Baseline to 96 Weeks.*
Variable

Change from Baseline

P Value†

Placebo
(N = 74)

Vitamin E
(N = 78)

Pioglitazone
(N = 70)

Vitamin E
vs. Placebo

Pioglitazone
vs. Placebo

−20.1

−37.0

−40.8

0.001

<0.001

−3.8

−21.3

−20.4

<0.001

<0.001

γ-Glutamyltransferase (U/liter)

−4.0

−14.0

−21.1

0.003

<0.001

Alkaline phosphatase (U/liter)

−3.8

−9.3

−12.0

0.008

0.004

0.56

0.07

Serum enzymes and bilirubin
Alanine aminotransferase (U/liter)
Aspartate aminotransferase (U/liter)

Total bilirubin (mg/dl)

0.06

0.04

−0.04

Lipids
Triglycerides (mg/dl)

−6.7

−0.6

−19.8

0.45

0.16

−9.6

−13.6

−11.4

0.25

0.50

Cholesterol (mg/dl)
Total
High-density lipoprotein

−1.9

−0.9

1.1

0.51

0.008

Low-density lipoprotein

−5.8

−12.0

−8.1

0.07

0.26

1.8

1.8

−3.1

0.81

0.006

Metabolic factors
Fasting serum glucose (mg/dl)
Insulin resistance‡

0.4

0.4

−0.7

0.80

0.03

Weight (kg)

0.7

0.4

4.7

0.65

<0.001

Body-mass index

0.4

0.1

1.8

0.50

<0.001

Waist circumference (cm)

0.2

−0.4

3.3

0.53

0.06

Body composition (% fat)

0

0.4

2.7

0.50

<0.001

SF-36 score, physical component

−0.3

0.4

−0.9

0.45

0.93

SF-36 score, mental component

0.4

−0.5

−1.9

0.76

0.23

Quality of life§

* The numbers of subjects listed for the three study groups are the numbers for whom data on alanine aminotransferase
levels were available. The total numbers of subjects included in the analyses of other variables ranged from 212 to 223.
The change from baseline is the value at 96 weeks minus the baseline value. To convert the values for bilirubin to micromoles per liter, multiply by 17.1. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129.
To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for glucose to
millimoles per liter, multiply by 0.05551.
† P values were calculated with the use of analysis-of-covariance models, regressing change from baseline to 96 weeks on
treatment group and baseline value of the outcome measure.
‡ The homeostasis model assessment for insulin resistance (HOMA-IR) was used to calculate insulin resistance, according to the following formula: (milligrams of glucose per deciliter × microunits of insulin per milliliter) ÷ 405. Diabetes
developed in four subjects assigned to the vitamin E group, and these subjects were not given an oral glucose-tolerance test at 96 weeks. Their HOMA-IR values at 96 weeks were imputed as the 95th percentile value at baseline.
Analyses were performed with the use of ranks owing to asymmetry in the distribution of change in HOMA-IR values.
§ Scores on the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) were standardized to the 1998 U.S.
general population with a mean (±SD) of 50±10.

ballooning was one of the criteria for the primary
outcome. The discrepancies between the results of
liver histologic assessments that were performed
locally to determine eligibility and the results of
assessments of deeper cuts of the same tissue
block that were performed centrally to determine
histologic baseline and outcome measures for use
in the study analyses may have been due to inter
observer variability, variable distribution of his
n engl j med 362;18

tologic findings in the different tissue sections,
or a potential bias due to the unblinded nature
of the local pathological review to determine eli
gibility.22-24
It is important not to overinterpret the data
on adverse events in this trial because the study
was not powered to test any safety-related hypoth
eses. The risk of bone fracture was not increased
with pioglitazone25; however, the number of post
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menopausal women included in the trial was too
small to assess any potential effect. Although dia
betes developed in subjects in the vitamin E group
but not in subjects in the other two groups, only
four subjects were affected, and this number is
smaller than the number that would be expected
in this patient population. Finally, cardiovascu
lar events occurred with equal frequency in all
three study groups, but, again, the trial was much
too small to detect meaningful differences in the
incidence of cardiovascular events.
Enthusiasm for the potential benefits of pio
glitazone and vitamin E must be tempered by the
finding that there was an improvement in histo
logic features in only 34% of the subjects who
received pioglitazone and 43% of those who re
ceived vitamin E, and steatohepatitis resolved in
only 47% and 36% of the subjects in those two
groups, respectively. Neither agent was associated
with a significant improvement in the mean fi
brosis score after 96 weeks of treatment. There
was also no significant reduction in portal in
flammation, which has been linked to advanced
disease.4,26 Given the certainty of relapse after
discontinuation of the drug, it is likely that which
ever drug is prescribed for nonalcoholic steato
hepatitis, it will need to be taken indefinitely.13,27
The weight gain among the subjects receiving
pioglitazone — which did not resolve after dis
continuation of the drug — also detracts from its
long-term usefulness. The unknown long-term
potential for adverse events with vitamin E and
pioglitazone therapies must be factored into the
decision about whether to use these agents.25,28,29
The decision about which specific therapy to
use for the treatment of nonalcoholic steatohepa
titis should include a consideration of both the
efficacy and the toxic effects of the therapy as
compared with those of other available therapies.
Preliminary studies provide a rationale for the use
of lifestyle intervention, bariatric surgery, phle
botomy, and a variety of drugs. However, the
usefulness of each of these therapeutic options
has not been validated in rigorously performed,
randomized, controlled trials. Our study provides
such evidence for vitamin E and pioglitazone;
however, this trial was not designed to compare

of
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vitamin E with pioglitazone, and no conclusions
can be drawn about their relative efficacy.
In summary, the results of this trial of pioglit
azone and vitamin E for the treatment of nonal
coholic steatohepatitis in adults without diabetes
showed that vitamin E was superior to placebo
and suggested that pioglitazone may also have ef
ficacy. Although only subjects who received vita
min E met the criteria for the prespecified primary
outcome measure, subjects who received pioglit
azone had significant improvement in other im
portant histologic features of nonalcoholic steato
hepatitis.
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University of California San Francisco; N. Chalasani, Indiana University; A.M. Diehl, Duke University; K. Kowdley, Virginia Mason
Medical Center; R. Loomba, University of California San Diego; A. McCullough, Case Western Reserve University; J. Molleston, Indiana
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Robuck (project scientist), L. Seeff; Johns Hopkins University Bloomberg School of Public Health (Data Coordinating Center), Baltimore:
J. Tonascia, P. Belt, F. Brancati, J. Clark, R. Colvin, M. Donithan, M. Green, M. Isaacson, W. Kim, L. Miriel, A. Sternberg, A. Ünalp, M.
Van Natta, I. Vaughn, L. Wilson, K. Yates.
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